Cargando…

Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.

Twenty-eight patients with advanced life-threatening metastatic malignant melanoma were treated with high dose (140-260 mgm-2) intravenous melphalan and autologous bone marrow. Cyclophosphamide "priming" 300 mgm-2 i.v. was given to 19 patients one week previously and this resulted in clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cornbleet, M. A., McElwain, T. J., Kumar, P. J., Filshie, J., Selby, P., Carter, R. L., Hedley, D. W., Clark, M. L., Millar, J. L.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1983
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011461/ https://www.ncbi.nlm.nih.gov/pubmed/6351883

Ejemplares similares

High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.
por: Pritchard, J., et al.
Publicado: (1982)

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
por: Zulian, G. B., et al.
Publicado: (1989)

Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.
por: McElwain, T. J., et al.
Publicado: (1979)

Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.
por: Millar, J. L., et al.
Publicado: (1978)

Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
por: Selby, P. J., et al.
Publicado: (1987)

Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.
por: Robinson, B. A., et al.
Publicado: (1985)

Effects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts.
por: Robinson, B. A., et al.
Publicado: (1986)

High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
por: Mbidde, E. K., et al.
Publicado: (1988)

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
por: Lakhani, S., et al.
Publicado: (1990)

Epidermal growth factor (hEGF) has no effect on murine intestine epithelial damage and regeneration after melphalan.
por: Robinson, B. A., et al.
Publicado: (1985)

Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
por: Hedley, D. W., et al.
Publicado: (1978)

Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas.
por: Pinkerton, C. R., et al.
Publicado: (1991)

Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
por: Currie, G. A., et al.
Publicado: (1975)

Colony growth and clonogenic cell survival in human melanoma xenografts treated with chemotherapy.
por: Selby, P. J., et al.
Publicado: (1980)

Melphalan transport into human malignant lymphoid cells differs from the murine equivalent in vitro.
por: Millar, B. C., et al.
Publicado: (1989)

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
por: Scott, R. N., et al.
Publicado: (1992)

Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
por: Taylor, P. R., et al.
Publicado: (1993)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.
por: Forgeson, G. V., et al.
Publicado: (1988)

Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.
por: Jones, A. L., et al.
Publicado: (1990)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
por: Seymour, L. K., et al.
Publicado: (1994)

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
por: Perren, T. J., et al.
Publicado: (1990)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Standard melanoma-associated markers do not identify the MM127 metastatic melanoma cell line
por: Haridas, Parvathi, et al.
Publicado: (2016)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

Oral Melphalan Therapy in Advanced Malignant Disease
por: Clifford, Peter, et al.
Publicado: (1963)

Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan.
por: Alberts, D. S., et al.
Publicado: (1981)

Melphalan uptake in relation to vascular and extracellular space of human lung-tumour xenografts.
por: Wist, E., et al.
Publicado: (1981)

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan
por: Nieto, Yago, et al.
Publicado: (2017)

Peripheral Neuropathy and VIth Nerve Palsy Related to Randall Disease Successfully Treated by High-Dose Melphalan, Autologous Blood Stem Cell Transplantation, and VIth Nerve Decompression Surgery
por: Foguem, C., et al.
Publicado: (2010)

Pharmacokinetic‐Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High‐Dose Melphalan for Autologous Stem Cell Transplant
por: Cho, Yu Kyoung, et al.
Publicado: (2018)

PB2193: IS HYPERHYDRATION NECESSARY FOR HIGH DOSE MELPHALAN CONDITIONING REGIMEN IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION?
por: Mora Argumánez, M., et al.
Publicado: (2022)

Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis
por: Hoshino, Junichi, et al.
Publicado: (2008)

Melphalan Culprit or Confounder in Acute Encephalopathy during Autologous Hematopoietic Stem Cell Transplantation?
por: Alayón-Laguer, Diógenes, et al.
Publicado: (2012)

Three-dimensional experiments and individual based simulations show that cell proliferation drives melanoma nest formation in human skin tissue
por: Haridas, Parvathi, et al.
Publicado: (2018)

Brain metastases in malignant teratoma: a review of four years' experience and an assessment of the role of tumour markers.
por: Kaye, S. B., et al.
Publicado: (1979)

Quantitative comparison of the spreading and invasion of radial growth phase and metastatic melanoma cells in a three-dimensional human skin equivalent model
por: Haridas, Parvathi, et al.
Publicado: (2017)

High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease.
por: Philip, T., et al.
Publicado: (1986)

High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index.
por: O'Brien, M. E., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_bm25ch6r207fleq2hhkeso3esg